Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients

This article was published in the following Dove Press journal: Drug Design, Development and Therapy
18 January 2016
Number of times this article has been viewed

Dear editor

Woollard and Kanmogne have generated an exhaustive review on maraviroc and its use in human immunodeficiency virus (HIV) infection. Within their interesting dissertation, they discuss about the maraviroc clinical test (MCT), a clinical approach developed in our group in order to decide candidate patients to receive maraviroc as part of a further combined antiretroviral therapy, as an alternative to genotypic and phenotypic tropism assays. Based on our results, they state that MCT could help to determine/confirm the genotypic/phenotypic HIV-1 tropism, particularly in patients with nonreportable results by Trofile. Subsequently, they note that “no concordance” between standard V3-based genotypic tropism assays and virological response to maraviroc monotherapy was found, according to previous results generated by our group. Finally, based on the results of Hernández-Novoa et al, they conclude that short-term maraviroc exposure cannot predict viral tropism in treatment-naïve patients.

In our opinion, MCT is an alternative tool to be used in clinical practice to decide CCR5-antagonist prescription in HIV-infected subjects, both in treatment-experienced and -naïve patients. Discordances between phenotypic and genotypic methods have been found. Moreover, our group developed MCT, a drug sensitivity test but not a tropism assay, and again discordances between MCT and different tropism methods including deep-sequencing were found. Hence, it has not been established as a “gold standard” to be used in clinical practice before prescribing maraviroc. We consider that the virological response to the drug should be the most important criteria in order to decide maraviroc prescription, and not a categorical tropism result. Therefore, we use MCT not just to confirm a genotypic/phenotypic tropism result and not particularly in patients with a nonreportable result by Trofile but in all patients.

Regarding the naïve scenario, our group has explored this issue in a recently published work, confirming that MCT is a reliable tool to decide maraviroc prescription in naïve HIV-infected subjects. In this work, most patients showed a significant viral load reduction during MCT and an excellent immunovirological evolution was shown once the subsequent CART was started after MCT; again, discordance rates were found between MCT and different tropism methods, similar to those found in treatment-experienced patients. Unfortunately, the review by Woollard and Kanmogne was accepted for publication just before the publication of this work, so they probably did not have time to include our data in their study.
Additionally, Woollard and Kanmogne consider that MCT cannot be used in naïve HIV-infected subjects based on data from Hernández-Novoa et al., because these authors concluded that this clinical test cannot be used as a surrogate marker of viral tropism in naïve patients. We agree with the conclusion of Hernández-Novoa et al, since MCT is not a surrogate marker of viral tropism but a clinical test based on the virological response to a short-term exposure to the drug, and provides discordant results with different tropism assays as previously reported.2,5,6 Hernández-Novoa et al show that patients with R5 or dual/mixed viral tropism according to Trofile® have similar virological responses to maraviroc monotherapy, reflecting the previously described discordance between the clinical approach and the phenotypic tropism method, as expected. Analyzing their data, we can see that 32/37 (85%) of their patients had virological response according to MCT (viral load reduction >1 log RNA copies/mL) while 5/37 (15%) did not, exactly the R5 and non-R5 expected percentages in HIV-1 treatment-naïve patients.8 In addition, given the MCT criteria, 9/37 (24%) of the patients had discordant results with Trofile® in their study, similar to previous studies.2,5–7 Besides, unlike Hernández-Novoa et al, in these mentioned studies we performed a follow-up of the patients proving the safety of the test according to the excellent immunovirological evolution after long-term cART started after MCT. Therefore, we consider that a misclassification by Trofile® and genotypic methods would be the more plausible explanation for the discordances observed with the virological response during maraviroc monotherapy exposure, probably due to the presence of low-level X4 variants with no clinical relevance.

Taken altogether, we think that MCT remains a very promising strategy to decide maraviroc prescription in HIV-infected patients, both treatment-experienced and naïve subjects, independent of the viral tropism result once the presence of low-level X4 variants seem to be clinically irrelevant.

Acknowledgments
We would like to acknowledge the patients who participated in this study. This work was supported by Redes Temáticas de Investigación en SIDA (ISCIII RETIC RD12/0017/0029) and Fondo de Investigación Sanitaria (PI12/02283).

Disclosure
A Gonzalez-Serna and M Genebat contributed equally as first authors. E Ruiz-Mateos and M Leal contributed equally as last authors. E Ruiz-Mateos has a grant from Fondo de Investigaciones Sanitarias (CP08/00172 and CPII014/00025). M Leal and E Ruiz-Mateos have grants from Pfizer/ViiV Healthcare. The authors report no other conflicts of interest in this communication.

References
Author’s reply
Shawna M Woollard
Georgette D Kanmogne
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA

Correspondence: Georgette D Kanmogne
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, 985800 Nebraska Medical Center, Omaha, NE, USA
Tel +1 402 559 4084
Fax +1 402 559 7495
Email gkanmogne@unmc.edu

Dear editor
We appreciate the insightful comments of Gonzalez-Serna et al, and their clarifications on the topic of maraviroc clinical test (MCT). In our manuscript,1 we reviewed and discussed MCT use as a surrogate marker for viral tropism. We concluded that MCT could not be used as an alternative approach to test for viral tropism based on a study by Hernández-Novoa et al,2 showing that treatment-naïve patients with dual/mixed tropic human immunodeficiency virus (HIV) strains showed a positive MCT response. However, we did not address the possibility of the MCT as a clinical alternative to genotypic and phenotypic tropism assays.

We agree that the clinical utility of the MCT should not be overlooked, especially in patients with nonreportable Trofile® results or when there are discordant results between genotypic and phenotypic tropism assays. However, we remain concerned about the possibility of the outgrowth of X4-tropic viruses. We believe that when X4 variants are present in subjects with dual/mixed tropic HIV strains, the fact that the levels of those initial X4 variants are low, and that subjects initially respond to MVC therapy, do not make the X4 variants clinically irrelevant. There are several studies showing that after initial success following antiretroviral therapy targeting non-X4 variants, even with significant virological and immunological responses, initial low-level X4 variants can outgrow3–5 and this often leads to resistance and treatment failure.3–6

Thus, these initial low levels of X4 variants can have major clinical implications and relevance.

The MCT may be more appropriate for infected treatment-naïve subjects, compared to infected treatment-experienced patients, as X4 variants in the viral reservoirs are more likely to have emerged in most patients in the latter group compared to treatment-naïve patients.7,8 This is corroborated by studies showing reduced viral loads in treatment-naïve patients with dual/mixed tropic HIV strains during the MCT,2,9 whereas another study performed in treatment-experienced patients with dual/mixed HIV strains showed no decrease in viral load during the MCT in the majority of patients.10 Maraviroc therapy, even in patients with low levels of X4 variants, may lead to the emergence of X4 variants from the viral reservoir,11–13 possibly due to increased fitness of the X4-tropic virus over R5-tropic virus.12 The long-term effects of the emergence of X4 variants during treatment with maraviroc remains unknown, but such a development could be clinically significant and relevant, and could be a major concern in patients with multiclass drug resistance.

The major limitations of the MCT studies thus far have been the low number of patients/sample size in each study, and the lack of data showing the efficacy of maraviroc-containing regimens in patients with a positive MCT at time points past 144 weeks.2,9,10,13–17 We look forward to future results with the MCT involving larger cohorts and longer follow-up time points.

Disclosure
The authors report no conflicts of interest in this communication.

References